human multiple myeloma tumor

GSK467 is a potent and selective inhibitor of KDM5 (JARID1)(Ki : 10 nM).

BCMA CARmRNA encodes a CAR protein targeting human BCMA and induces temporary CAR expression in T cells without the necessity for permanent genetic modification. It is used in cancer research as it targets BCMA, a member of the tumor necrosis factor receptor superfamily 17 (TNFRSF17), also known as B-cell maturation antigen (CD269). This receptor supports B-cell survival and plays a role in regulating humoral immunity. Notably, BCMA is highly expressed in multiple myeloma and serves as a biomarker for its diagnosis.

PC-046 is a potent tubulin-binding agent, which was originally identified for development based on selective activity in deleted in pancreas cancer locus 4 (DPC4/SMAD4) deficient tumors. PC-046 has growth inhibitory activity in a variety of tumor types in vitro, and efficacy in SCID mice was shown in human tumor xenografts of MV-4-11 acute myeloid leukemia, MM.1S multiple myeloma, and DU-145 prostate cancer. Pharmacokinetic studies demonstrated relatively high oral bioavailability (71 %) with distribution to both plasma and bone marrow. No myelosuppression was seen in non-tumor bearing SCID mice given a single dose just under the acute lethal dose. The COMPARE algorithm in the NCI-60 cell line panel demonstrated that PC-046 closely correlated to other known tubulin destabilizing agents (correlation coefficients ≈0.7 for vincristine and vinblastine). Mechanism of action studies showed cell cycle arrest in metaphase and inhibition of tubulin polymerization. Overall, these studi......

Linvoseltamab (REGN5458) is a fully human BCMA x CD3 bispecific T-cell engaging antibody. This product simultaneously binds to B-cell maturation antigen (BCMA) on multiple myeloma cells and CD3 on T cells, inducing T-cell directed killing of tumor cells. It plays a significant role in the research of treatment mechanisms for relapsed/refractory multiple myeloma.

MSH-TP15e is a human-derived monoclonal antibody inhibitor that targets intercellular adhesion molecule-1 (ICAM-1). By recruiting natural killer cells, MSH-TP15e significantly induces antibody-dependent cell-mediated cytotoxicity (ADCC) activity, thereby inhibiting tumor cell growth. MSH-TP15e shows potential for research in multiple myeloma (MM).

Ramantamig is a humanized monoclonal antibody that targets human CD3ε, GPRC5D, and TNFRSF17 [tumor necrosis factor receptor superfamily member 17]. It holds potential for cancer research, particularly focusing on hematologic malignancies such as multiple myeloma.